<DOC>
	<DOCNO>NCT01981837</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetics , pharmacodynamics exploratory clinical activity ALN-TTRSC ( revusiran ) Patients Transthyretin ( TTR ) Cardiac Amyloidosis .</brief_summary>
	<brief_title>Phase 2 Study Evaluate ALN-TTRSC ( Revusiran ) Patients With Transthyretin ( TTR ) Cardiac Amyloidosis</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>TTR cardiac amyloidosis ; Women childbearing potential ( WOCBP ) must negative pregnancy test , breast feeding , must willing use 2 highly effective method contraception ; Male subject agree use appropriate contraception ; Adequate blood count , liver , renal heart function ; Adequate Karnofsky performance status ; Adequate New York Heart Association ( NYHA ) Classification Score ; Clinically stable heart medication ; Adequate 6minute walk test ; Willing give write informed consent willing comply study requirement . Known human immunodeficiency virus ( HIV ) positive status know suspected systemic bacterial , viral , parasitic , fungal infection ; Subjects history multiple drug allergy intolerance SC injection ; Received investigational agent tafamidis , diflunisal , doxycycline tauroursodeoxycholic acid , investigational device within 30 day prior first dose study ; Uncontrolled hypertension , ischemic heart disease cardiac arrhythmia ; Untreated hypo hyperthyroidism ; Prior major organ transplant ; Considered unfit study Principal Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>RNAi therapeutic</keyword>
</DOC>